Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Monte Rosa Therapeutics (GLUE) Operating Margin (2024 - 2025)

Monte Rosa Therapeutics' Operating Margin history spans 2 years, with the latest figure at 1787.67% for Q4 2025.

  • For Q4 2025, Operating Margin fell 191857.0% year-over-year to 1787.67%; the TTM value through Dec 2025 reached 43.83%, down 2436.0%, while the annual FY2025 figure was 43.83%, 2436.0% down from the prior year.
  • Operating Margin reached 1787.67% in Q4 2025 per GLUE's latest filing, down from 258.26% in the prior quarter.
  • In the past five years, Operating Margin ranged from a high of 130.9% in Q4 2024 to a low of 3284.49% in Q1 2024.